Scarlet raises $50 million to expand AI medical device certification
Scarlet has raised a $50 million Series B led by Headline as it expands a business built around assessing AI and software medical devices. Headline announced the investment on October 12, backing a company whose service sits between product development and the evidence needed to bring regulated technology to market. Headline investment announcement.
Notion Capital joined the round alongside existing investors including Atomico, Creandum and Kindred. In its own announcement, Notion said Scarlet plans to expand its certification offering, add experts and AI agents, and increase its presence in the United States and Asia Pacific. Notion Capital announcement.
Software changes the assessment workload
Scarlet founders James Dewar and Jamie Cox previously worked on software medical devices at Babylon Health, according to Headline. The investor says their experience with assessment delays helped shape Scarlet’s focus on specialised certification for software and AI. Founder background.
Notion’s investment thesis centres on repeated product changes. It argues that AI tools accelerate development and regulatory submissions while the devices themselves keep evolving. A certification service must therefore handle continuing updates as well as an initial assessment. That is the demand Scarlet’s investors expect the new funding to help it meet. Investor view of the market.
Human reviewers remain part of the process
Headline describes a workflow in which technology processes and organises submitted documentation, while qualified reviewers make regulatory judgments. It says assessment findings link to evidence and relevant requirements, giving customers and regulators a record of the basis for a decision. These are descriptions from the investor, rather than an independent audit of review quality. Assessment workflow.
The United States role has clear limits
The FDA’s own registry lists Scarlet NB B.V. among recognised organisations in its 510(k) Third Party Review Program. The database makes clear that a reviewer’s scope is tied to eligible device product codes. This provides a regulatory source for Scarlet’s US role beyond its investors’ description. FDA reviewer registry.
Under that voluntary programme, an accredited organisation can review certain eligible devices and submit its assessment and recommendation to the FDA. The agency makes the final determination. It can review all or part of a submission again when the earlier assessment did not apply the criteria appropriately or has substantial quality problems. FDA programme explanation.
That distinction matters for understanding Scarlet’s expansion. Increasing review capacity can support manufacturers preparing eligible submissions, while the FDA retains its decision making role. The funding announcement does not change those responsibilities or establish a guaranteed clearance timetable for a particular device. Review responsibilities.
Laboratory pipetting equipment. Illustrative photograph by Louis Reed on Unsplash, used under the Unsplash License.
